Affimed to Report Second Quarter 2020 Financial Results & Corporate Update August 11, 2020 August 4, 2020
Affimed Announces Presentation of Data on Genentech’s RO7297089 and AFM24, Both Innate Cell Engagers Developed from Affimed’s ROCK® Platform, at AACR Virtual Annual Meeting II June 22, 2020
Affimed Announces Successful Completion of First Dose Cohort in First-in-Human Phase 1/2A Study of AFM24 for the Treatment of Advanced EGFR-Expressing Solid Tumors Including Colon, Lung and Other Cancers June 17, 2020
Affimed to Report First Quarter 2020 Financial Results & Corporate Update June 23, 2020; Company to Participate in Virtual BMO Prescriptions for Success Healthcare Conference June 16, 2020
